E Fund Management Co. Ltd. Invests $314,000 in Morphic Holding, Inc. (NASDAQ:MORF)

E Fund Management Co. Ltd. purchased a new position in shares of Morphic Holding, Inc. (NASDAQ:MORF) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 10,888 shares of the company’s stock, valued at approximately $314,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP grew its holdings in shares of Morphic by 48.5% during the third quarter. Wellington Management Group LLP now owns 3,421,820 shares of the company’s stock worth $78,394,000 after purchasing an additional 1,117,985 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Morphic by 10.5% in the third quarter. Vanguard Group Inc. now owns 2,107,410 shares of the company’s stock valued at $48,281,000 after acquiring an additional 200,772 shares during the last quarter. Federated Hermes Inc. boosted its holdings in Morphic by 13.1% in the fourth quarter. Federated Hermes Inc. now owns 1,000,000 shares of the company’s stock valued at $28,880,000 after acquiring an additional 115,975 shares during the last quarter. Jennison Associates LLC bought a new stake in Morphic in the fourth quarter valued at approximately $17,818,000. Finally, Silverarc Capital Management LLC boosted its holdings in Morphic by 134.2% in the third quarter. Silverarc Capital Management LLC now owns 590,829 shares of the company’s stock valued at $13,536,000 after acquiring an additional 338,520 shares during the last quarter. 94.25% of the stock is currently owned by institutional investors.

Morphic Trading Down 0.7 %

MORF stock traded down $0.20 during trading on Thursday, hitting $29.13. The company had a trading volume of 281,791 shares, compared to its average volume of 492,008. The business has a 50-day moving average of $31.94 and a 200-day moving average of $29.51. Morphic Holding, Inc. has a one year low of $19.34 and a one year high of $63.08. The stock has a market cap of $1.46 billion, a PE ratio of -8.32 and a beta of 1.48.

Morphic (NASDAQ:MORF) last announced its earnings results on Thursday, February 22nd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.05). Research analysts forecast that Morphic Holding, Inc. will post -4.07 EPS for the current year.

About Morphic

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.